Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VRDN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Veligrotug FDA approved Jun 2026 · Lumvoa |
Thyroid Eye Disease | Phase 3 · NCT06179875 | Completed |
| veligrotrug (LUMVOA™) | Thyroid Eye Disease | Phase 4 · NCT07832136 | Not yet recruiting |
| VRDN-003 | Thyroid Eye Disease (TED) | Phase 3 · NCT06812325 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VRDN holds $955.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $99M/quarter from operations, an estimated runway of 28.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VRDN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Bellevue Group AG | Institution (13G, 5%+) | 6,726,144 | 5.92% | 2026-03-31 |
| Paradigm BioCapital Advisors LP | 5%+ holder (13G) | 6,723,788 | 5.92% | 2026-06-30 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 5,748,426 | 5.06% | 2026-06-30 |
| Point72 Asset Management, L.P. | 5%+ holder (13G) | 5,687,507 | 5.01% | 2026-08-19 |
| Fairmount Funds Management LLC Director, 10% owner |
Insider | 5,090,928 | 4.48% | 2026-05-11 |
| Radhika Tripuraneni Chief Medical Officer · +425,650 options |
Insider | 40,000 | 0.04% | 2026-08-14 |
| Stephen F. Mahoney President and CEO, Director · +1.06M options |
Insider | 33,349 | 0.03% | 2026-03-03 |
| Thomas W. Beetham Chief Operating Officer · +430,591 options |
Insider | 13,361 | 0.01% | 2026-03-03 |
| Seth Harmon Chief Financial Officer · +272,058 options |
Insider | 7,850 | 0.01% | 2026-03-03 |
Share count 113,558,449 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-06-30 | Lumvoa™ (veligrotug-vvze) | BLA | +7.7% | -2.2% | — |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VRDN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →